Pharmacokinetic evaluation of gemcitabine and 2′,2′-difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors-Reference-Cited by-同舟云学术

Pharmacokinetic evaluation of gemcitabine and 2′,2′-difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors

Published:2006-05 Issue: Volume:17 Page:v142-v147
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cattel L.,Airoldi M.,Delprino L.,Passera R.,Milla P.,Pedani F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/suppl_5/v142/477839/mdj970.pdf

Reference27 articles.

1. Summary of product characteristics;Eli Lilly and Co,1997

2. Preclinical, pharmacologic and phase I studies of gemcitabine;Storniolo;Semin Oncol,1997

3. Gemcitabine: preclinical pharmacology and mechanisms of action;Plunkett;Semin Oncol,1996

4. Gemcitabine: metabolism, mechanism of action and self potentiation;Plunkett;Semin Oncol,1995

5. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine;Abbruzzese;J Clin Oncol,1991

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybrid Nanoparticles of Extracellular Vesicles and Gemcitabine Prodrug-Loaded Liposomes with Enhanced Targeting Ability for Effective PDAC Treatment;ACS Applied Bio Materials;2024-09-04

2. Continuous iontronic chemotherapy reduces brain tumor growth in embryonic avian in vivo models;Journal of Controlled Release;2024-05

3. The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study;European Urology Open Science;2024-04

4. Concurrent chemoradiation with low-dose and long-duration weekly infusion of gemcitabine in unresectable squamous cell carcinoma of head and neck (SCCHN);Journal of Cancer Research and Therapeutics;2024-04

5. Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model;Cell Death Discovery;2024-03-29